Crystal structure and catalytic mechanism of the essential m1G37 tRNA methyltransferase TrmD from Pseudomonas aeruginosa

• DOI: 10.1261/rna.066746.118
• Publication Date: 2019-08-09T22:44:10Z
• Authors: Juthamas Jaroensuk; Yee Hwa Wong; Wenhe Zhong; Chong Wai Liew; Somchart Maenpuen; Abbas E. Sahili; Sopapan Atichartp...; Yok Hian Chionh; Qianhui Nah; Narumon Thongdee; Megan E. McBee; Erin G. Prestwich; Michael S. DeMott; Pimchai Chaiyen; Skorn Mongkolsuk; Peter C. Dedon; Julien Lescar; Mayuree Fuangthong
• Keywords: S-Adenosylmethionine; tRNA Methyltransferases; 0303 health sciences; Protein Conformation; Crystallography, X-Ray; Article; Catalysis; Substrate Specificity; Kinetics; 03 medical and health sciences; RNA, Transfer; Pseudomonas aeruginosa; Protein Binding

The tRNA (m1G37) methyltransferase TrmD catalyzes m1G formation at position 37 in many tRNA isoacceptors and is essential in most bacteria, which positions it as a target for antibiotic development. In spite of its crucial role, little is known about TrmD in Pseudomonas aeruginosa (PaTrmD), an important human pathogen. Here we present detailed structural, substrate, and kinetic properties of PaTrmD. The mass spectrometric analysis confirmed the G36G37-containing tRNAs Leu(GAG), Leu(CAG), Leu(UAG), Pro(GGG), Pro(UGG), Pro(CGG), and His(GUG) as PaTrmD substrates. Analysis of steady-state kinetics with S-adenosyl-l-methionine (SAM) and tRNALeu(GAG) showed that PaTrmD catalyzes the two-substrate reaction by way of a ternary complex, while isothermal titration calorimetry revealed that SAM and tRNALeu(GAG) bind to PaTrmD independently, each with a dissociation constant of 14 ± 3 µM. Inhibition by the SAM analog sinefungin was competitive with respect to SAM (Ki = 0.41 ± 0.07 µM) and uncompetitive for tRNA (Ki = 6.4 ± 0.8 µM). A set of crystal structures of the homodimeric PaTrmD protein bound to SAM and sinefungin provide the molecular basis for enzyme competitive inhibition and identify the location of the bound divalent ion. These results provide insights into PaTrmD as a potential target for the development of antibiotics.